KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

NEODEX EYE/EAR DROPS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

 

GENERIC NAME:

DEXAMETHASONE SODIUM PHOSPHATE AND NEOMYCIN SULFATE

 

MANUFACTURER:

AMMAN

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Dermatitis, atopic

Dermatitis, contact

Dermatitis, exfoliative

Dermatitis, seborrheic

 

SIDE EFFECTS:

Bacterial keratitis

burning or stinging of the ear

Cushing's syndrome

dermatological changes

diabetes mellitus

endocrine disturbances

fluid or electrolyte disturbances

gastrointestinal changes

hypokalemic syndrome

musculoskeletal changes

neurological changes

persistent fungal infections of the ear

muscle wasting

thromboembolism

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

Congestive heart failure

Diabetes mellitus

Epilepsy

Glaucoma

Hypertension

Infections, ear, acute

Infections, ear, chronic

Otitis media, especially in children

Osteoporosis

 

ADULT DOSE:

Topical, to the ear canal, 3 or 4 drops of a 0.1% (phosphate) solution two or three times a day. After a favorable response is obtained, dosage may be gradually reduced if required to provide continuing control of symptoms prior to discontinuation.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Topical, to the ear canal, 3 or 4 drops of a 0.1% (phosphate) solution two or three times a day. After a favorable response is obtained, dosage may be gradually reduced if required to provide continuing control of symptoms prior to discontinuation.  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Topical, to the ear canal, 3 or 4 drops of a 0.1% (phosphate) solution two or three times a day. After a favorable response is obtained, dosage may be gradually reduced if required to provide continuing control of symptoms prior to discontinuation.

 

 

PREVIOUS

  

NEXT